Compare iMMCO Diagnostics vs Minomic International
Customers evaluate the quality of iMMCO Diagnostics's products using the following success metrics.
Overview
iMMCO Diagnostics is based in United States
IMMCO Diagnostics provides high-quality diagnostic test kits and lab testing services worldwide for the screening of autoimmune disorders. IMMCO Diagnostics incorporates working on research, clinical laboratory expertise, and medical devices into an approach to autoimmune diagnostics.
Minomic International is based in Australia
Minomic International is an Australian company that specializes in the commercialization of tests for solid tumors in cancers such as prostate, bladder, and pancreatic. The company's main product is a diagnostic test for the early detection of prostate cancer, which works by detecting biomarkers present in the blood of patients. The test is designed to provide more accurate results than existing blood tests for prostate cancer, helping to differentiate aggressive cancer from non-aggressive or no cancer before invasive and expensive biopsies are carried out. It is based in Macquarie Park, New South Wales.
Demo Video
Leadership
William J. Maggio (Owner)
Brad Walsh (Chief Executive Officer)
Funding
Investors
Paycheck Protection Program and Summit Partners
Probiomics and NuSep
Product
Information not available because iMMCO Diagnostics has not claimed their profile.
Work for iMMCO Diagnostics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for iMMCO Diagnostics?
Claim your profile now.
Why Minomic International beats iMMCO Diagnostics
Benefits
Products
MiCheck® Prostate
Blood test to determine Risk score for aggressive prostate cancer
Customers
Known Partners
Why They Buy